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against serum nucleases and rapid clear-
ance of siRNA by the kidney due to its 
small size (<10 nm). [ 2 ] Moreover, siRNA 
cannot cross the cell membrane as its 
backbone is too negatively charged. [ 1c ] 
Therefore, therapeutic siRNA requires 
transfection agents that protect oligonucle-
otides and traffi c them into cells. Viral-, [ 3 ] 
lipid-, [ 4 ] or polymer-based [ 5 ] delivery sys-
tems have been reported. However, virus-
like particles are prone to be cleared 
by virus-specifi c antibodies [ 6 ] and lipid-
based siRNA delivery systems are rap-
idly removed by the liver and spleen. [ 7 ] 
Polymers and dendrimers used for siRNA 
delivery often exhibit toxicity and nonspecifi c cell uptake 
because they are often highly positively charged. [ 8 ] Such draw-
backs of transfection agents are reasons that RNA interference 
(RNAi) has not reached its full clinical potential. New concepts 
for siRNA delivery systems are therefore of great interest. [ 1a,c ,  6–9 ] 
 Protein cages are large, hollow, and well-defi ned macro-
molecular structures, which are built from multiple copies of 
one or more protein subunits. [ 10 ] Their capsule-like structure 
in combination with the possibility to precisely modify their 
exterior surface and their cavity by genetic and chemical means 
has led to a range of nanotechnological and biomedical applica-
tions. [ 10,11 ] Protein cages that have been explored for the delivery 
of drugs or contrast agents include viral capsids and virus-like 
particles, [ 12 ] ferritins, [ 13 ] heat shock proteins, [ 14 ] and chaper-
onins. [ 15 ] However, most protein cages have small pores that 
restrict drug delivery applications to small molecules or require 
therapeutic macromolecules to bind to their outer surface. 
 The pores of chaperonins (≈7 nm in diameter) are among 
the largest found in protein cages and allow macromolecules 
such as proteins up to 50 kDa [ 11a ,  16 ] and polymers [ 11b ] to dif-
fuse in and out of the cavities without affecting the capsule-like 
structure of the protein. For this reason, thermosome (THS) 
was selected as the protein cage to develop a siRNA delivery 
platform. THS is a group II chaperonin from the archaea 
 Thermoplasma acidophilum with a barrel shaped quaternary 
structure ≈16 nm in diameter. It is composed of 16 alternating 
α- and β-subunits, which form two hemispheres with a pseudo 
eightfold symmetry. Each hemisphere encloses a cavity. How-
ever, chaperonins do not naturally bind nucleic acids. In order 
to encapsulate siRNA into THS, the polycationic dendrimer 
poly(amidoamine) (PAMAM), which can complex siRNA via 
electrostatic interactions, [ 5d ,  17 ] was therefore conjugated into 
the cavities ( Figure  1 ). The THS–PAMAM conjugate could 
be loaded with siRNA and protected the oligonucleotide from 
degradation by RNase. The protein–polymer hybrid was able 
 The group II chaperonin thermosome (THS) is a hollow protein nanoparticle 
that can encapsulate macromolecular guests. Two large pores grant access 
to the interior of the protein cage. Poly(amidoamine) (PAMAM) is conjugated 
into THS to act as an anchor for small interfering RNA (siRNA), allowing to 
load the THS with therapeutic payload. THS–PAMAM protects siRNA from 
degradation by RNase A and traffi cs KIF11 and GAPDH siRNA into U87 
cancer cells. By modifi cation of the protein cage with the cell-penetrating 
peptide TAT, RNA interference is also induced in PC-3 cells. THS–PAMAM pro-
tein–polymer conjugates are therefore promising siRNA transfection reagents 
and greatly expand the scope of protein cages in drug delivery applications. 
This is an open access article under the terms of the Creative Commons 
Attribution License, which permits use, distribution and reproduction in 
any medium, provided the original work is properly cited.
 1.  Introduction 
 Specifi c short double-stranded RNA, the so-called small inter-
fering RNA (siRNA), induces the enzymatic breakdown of 
complementary messenger RNA in the cytosol. By interfering 
with the cellular pathway of disease-related proteins, siRNA is 
a promising drug, e.g., against cancer. [ 1 ] Moreover, siRNA has 
become an important tool for fundamental biological research, 
as it allows to knockdown gene expression in vitro. [ 1a ] How-
ever, some intrinsic problems must be overcome for effective 
delivery of siRNA into cells, such as the instability of RNA 
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to deliver siRNA into U87 cells and induced gene silencing. In 
order to demonstrate the possibility to further equip the pro-
tein cage with advanced functionalities, THS–PAMAM was 
decorated with the cell-penetrating peptide TAT. [ 18 ] This modi-
fi cation induced uptake and gene silencing in a cell line that 
otherwise did not respond to THS–PAMAM. 
 2.  Results and Discussion 
 2.1.  Conjugation of Dendrimer into the Protein Cage 
 For the conjugation of PAMAM (generation 4, ethylenedi-
amine core) into the cavity of THS, linkers were chosen that 
form a covalent and stable resonance-stabilized bis-arylhy-
drazone between THS and PAMAM (Figure  1 ). This linker 
chemistry has the advantage that the conjugation is stable 
in a wide pH range and that it can be quantifi ed by UV–Vis 
spectroscopy. [ 19 ] Cysteines (Cys) in the THS cavities were fi rst 
reacted with the heterobifunctional linker maleimido trioxa-
6-formylbenzamide (MTFB). [ 11a ] Their location within the THS 
is depicted as red residues in Figure  1 a. 3.8 ± 0.2 Cys per THS 
were modifi ed with MTFB, as determined by UV-Vis spectros-
copy (Table S1, Supporting Information). In parallel, PAMAM 
was modifi ed with a heterobifunctional linker featuring an 
activated ester and a 6-hydrazino-nicotinamide group (HyNic). 
The degree of modifi cation could be controlled by the con-
centration of HyNic in the reaction mixture (Figure S1, Sup-
porting Information). 
 For further experiments, reaction conditions were chosen 
that resulted in approximately four HyNic groups per PAMAM, 
which means that about 1/16 of the dendrimer’s primary 
amine groups were modifi ed. In a fi nal step, THS–MTFB was 
incubated with an excess of PAMAM–HyNic overnight to con-
jugate PAMAM into the THS. A kinetic study of the conjuga-
tion reaction showed that 80% of the THS–PAMAM bonds 
formed within 3 h (Figure S2, Supporting Information). The 
protein–polymer conjugate was purifi ed by size exclusion chro-
matography ( Figure  2 a). It eluted as a high molecular weight 
fraction at an elution volume of 35 mL and could be detected 
simultaneously at 280 nm (resulting from the absorbance of 
THS–PAMAM) and at 350 nm (resulting from the bis-aryl-
hydrazone linker). A second fraction at an elution volume of 
65 mL absorbed only in the 280 nm channel. It contained the 
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 Figure 1.  Structure of a THS and schematic depiction of siRNA delivery with a THS–PAMAM conjugate. a) Cut away view of a thermosome (green). 
Cysteines on the inside surface (red) serve as attachment points for conjugation reactions. To illustrate the proportion of protein cage and dendrimer, a 
model of PAMAM and the bis-arylhydrazone linker (blue) was placed into a cavity of THS. b) PAMAM conjugation to the cavity of THS, siRNA binding 
to THS–PAMAM and transfection of cells by THS–PAMAM conjugate. c) Conjugation strategy to link PAMAM into THS. Cys of THS were modifi ed with 
the heterobifunctional linker MTFB. PAMAM was modifi ed with the heterobifunctional linker HyNic. After purifi cation of the products from unreacted 
linkers, THS–MTFB and PAMAM–HyNic were mixed in order to react to THS–PAMAM.
 Figure 2.  a) Size exclusion chromatogram of the purifi cation of 
THS–PAMAM from excess of PAMAM, recorded at 280 nm (blue), and 
350 nm (red). b) UV–Vis spectra of THS–PAMAM (red; 5.8 × 10 −6  M ), 
THS (blue; normalized to 5.8 × 10 −6  M ), and PAMAM (green; normalized 
to 21.3 × 10 −6  M ).
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excess of PAMAM that was not bound to THS. The baseline-
separated elution peaks illustrate the successful separation 
of THS–PAMAM conjugate from free PAMAM. Native poly-
acrylamide gel electrophoresis (PAGE), transmission electron 
microscopy (TEM), and cryo-TEM reveal that the integrity of the 
protein cage was not affected by the conjugation of PAMAM 
(Figure S3–S5, Supporting Information). The UV–Vis spec-
trum of the conjugate showed the absorption of proteins and 
PAMAM at 280 nm and a peak at 354 nm that is characteristic 
for the bis-arylhydrazone linker (Figure  2 b). We calculated from 
such spectra that 3.8 ± 0.2 hydrazone bonds per THS formed, 
suggesting that all of the modifi ed cysteines in the THS were 
linked to PAMAM. 
 The change in molar mass of THS subunits due to PAMAM 
conjugation was analyzed with SDS–PAGE ( Figure  3 a). The 
THS subunits have a molecular weight of ≈58 kDa. PAMAM 
exhibits a smeared band with a maximum slightly above 20 kDa. 
THS–PAMAM shows additional smeared lines at higher mole-
cular weight than the THS subunits. In order to distinguish 
whether these new bands originate from PAMAM or not, the 
dendrimer was modifi ed with an UV-active dye (Atto647) and 
conjugated into the THS. While the THS subunits are not vis-
ible in the UV image of the gel, most of the new bands in the 
conjugate are (Figure  3 a). Therefore, it can be concluded that 
PAMAM is covalently bound to THS subunits. Moreover, the 
gel shows that there was no free PAMAM in the THS–PAMAM 
solutions. In order to assess the location of the dendrimer in 
the conjugates, gold nanoparticles were bound to PAMAM that 
was then conjugated to THS. Cryo-TEM revealed gold nano-
particles (AuNP) within THS, confi rming that the dendrimer 
was encapsulated into the protein cage (Figure  3 b; Figure S5, 
Supporting Information). 
 2.2.  Binding of siRNA to THS–PAMAM 
 Binding of siRNA to THS–PAMAM was demonstrated with 
an electrophoretic mobility shift assay (EMSA). siRNA that 
was incubated with THS–PAMAM migrated only a few milli-
meters in the gel, while free siRNA moved farther ( Figure  4 a). 
Incubation of siRNA with THS (i.e., without PAMAM) had no 
infl uence on the migration of the nucleic acid. These results 
indicate that siRNA bound to the PAMAM within THS and that 
the dendrimer is necessary to convert THS into a nucleotide 
delivery vehicle. The reversible character of this complexation 
was demonstrated by the addition of SDS. [ 20 ] THS–PAMAM 
released siRNA that migrated as fast as free siRNA in the elec-
trophoresis gel (Figure  4 a). The additional band in sample 
2 and 4 does not originate from a siRNA complex but results 
from an interaction between SDS and THS–PAMAM. 
 After rigorous separation of free siRNA from THS–PAMAM, 
the amount of siRNA bound to THS–PAMAM was measured 
by UV–Vis spectroscopy (Figure  4 b). The presence of siRNA 
caused an increase of absorbance at 260 nm, which is the 
characteristic absorbance band of nucleic acids. These spectra 
allowed calculating that on average one siRNA was captured by 
each THS–PAMAM. 
 The morphology of complexes between siRNA and THS–
PAMAM was characterized with TEM and dynamic light scat-
tering (DLS) (Figure S6, Supporting Information). TEM images 
show that the protein cage–polymer conjugate maintained 
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 Figure 3.  SDS-PAGE of THS (1), THS–PAMAM (2), THS–PAMAM–
Atto647 (3), PAMAM–Atto647 (4) and PAMAM (5), stained with 
Coomassie Blue (left lanes) and inverted fl uorescence image (right lanes). 
b) Cryo-TEM images of THS (left) and THS–PAMAM–AuNP (right); scale 
bars: 50 nm.
 Figure 4.  Binding of siRNA by THS–PAMAM. a) EMSA of various combi-
nations of siRNA, THS–PAMAM, and SDS. b) UV–Vis spectrum of THS–
PAMAM (green) and THS–PAMAM–siRNA (blue).
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its typical spherical structure upon binding of siRNA. Some 
protein nanoparticles appear to have aggregated. This obser-
vation was confi rmed by DLS, which measured an average 
particle hydrodynamic diameter of 98.0 ± 18.3 nm. In contrast, 
a hydrodynamic diameter of 14.6 ± 2.2 nm was measured for 
THS–PAMAM without siRNA. Most likely, some siRNA bound 
to more than one cationic dendrimer and therefore connected 
THS–PAMAM particles. 
 2.3.  Protection of siRNA from Degradation 
 For siRNA delivery, it is crucial to protect siRNA from degradation 
by nucleases, as these enzymes are ubiquitously present in extra-
cellular fl uids. [ 8 ] Free siRNA was degraded by RNase A to 50% 
of its original concentration in less than 5 min, whereas it took 
more than 40 min to degrade siRNA bound to THS–PAMAM 
to 50% ( Figure  5 ). Similar results were found with siRNA com-
plexed by PAMAM. Therefore, the protein–dendrimer conjugate 
stabilized siRNA against enzymatic degradation with a similar 
effi ciency than the established dendritic delivery agent. [ 5d ] 
 2.4.  Cell Uptake of THS 
 Several cell-lines (PC-3, HeLa, MCF-7, CHO-K1, HUVEC & U87) 
were tested for the uptake of dye-labeled THS (THS-Atto647) 
with fl ow cytometry (FACS) ( Figure  6 a, Table S2, Supporting 
Information). Only U87 interacted strongly with the chaperonin, 
possibly because different receptors induce internalization. [ 11f  ] 
The results suggest that U87 cells are suitable targets for siRNA 
delivery by the protein cage. The interaction of THS–Atto647 
with U87 cells was further analyzed with a confocal laser scan-
ning microscope (CLSM) to locate THS–Atto647 in or on the 
cells (Figure  6 b). After incubating the cells for 30 min in a solu-
tion of THS–Atto647, the protein cage was taken up into the 
cytoplasm of the cells. It did not bind to the cell membrane and 
it was not translocated to the nucleus. Additionally, the cells were 
treated with the dye LysoTracker that stains acidic cell compart-
ments. This allows to assess if THS–Atto647 accumulates, e.g., 
in lysosomes. Most of THS–Atto647 was not co-localized with 
LysoTracker, allowing to conclude that the uptake either occurs 
via nonacidic compartments or that THS rapidly escapes from 
endosomes. The intracellular location of THS-Atto647 did not 
change at longer incubation time of 2 h (Figure  6 b). Control 
experiments in which U87 cells were incubated with free Atto647 
showed some uptake into the cells, but most of the dye was co-
localized with the cell membrane. Moreover, dye agglomeration 
occurred (Figure S7, Supporting Information). Taken together, 
these results prove that the protein cage entered the cells. 
 As THS was rapidly taken up by U87 cells, it was tested if 
THS–PAMAM can deliver siRNA into the cytosol and trigger 
gene silencing. To this end, the protein–dendrimer conjugate 
was loaded with a siRNA that interferes with the messenger 
RNA of KIF11, a protein of the kinesin family. A knockdown 
of KIF11 by siRNA induces stop of proliferation, and nona-
poptotic, lysosomal cell death. [ 21 ] KIF11 siRNA complexed 
with THS–PAMAM was added to U87 cells (10 pmol per well 
siRNA) and the cell viability was measured after 72 h. As a 
negative control, THS–PAMAM was used to deliver scrambled 
siRNA (10 pmol per well) to these cells. THS–PAMAM/KIF11 
siRNA reduced the viability of the cells to 79% ± 17% normal-
ized to non-treated cells. THS–PAMAM with scrambled siRNA 
( Figure  7 a) did not affect the viability (106% ± 28%). Thus, 
THS–PAMAM/KIF11 siRNA resulted in a reduction of U87 cell 
viability by 25% when compared with THS–PAMAM with 
scrambled siRNA (Figure  7 a). Even though the error bars of the 
two sets of measurements overlap to some extent, the differ-
ence between KIF11 siRNA and scrambled siRNA is signifi cant 
(signifi cance level in a two-sided Student’s t-test:  p = 0.029). 
These transfection results are comparable to other studies on 
KIF11 siRNA delivery, e.g., using lipid-coated poly(lactic- co -
glycolic acid) nanoparticles as transfection agent. [ 22 ] In contrast, 
PAMAM without THS was highly cytotoxic and reduced the cell 
viability to 13% ± 1%, independent of the presence of siRNA 
or the type of siRNA (Figure  7 a and Figure S8, Supporting 
Information). We used the same concentration of PAMAM 
(0.38 × 10 −6  M ) as in the test with the THS–PAMAM conju-
gates in order to allow for a direct comparison of the two sets of 
experiments. These results show that PAMAM alone cannot be 
used as siRNA delivery reagent at these conditions and stresses 
the importance of encapsulating PAMAM into the protein cage, 
thereby shielding the positive charges of PAMAM which are 
the source of the dendrimer’s toxicity. 
 To set these fi ndings into perspective, U87 cells were trans-
fected with KIF11 siRNA and scrambled siRNA using Lipo-
fectamine RNAiMAX (RNAiMAX) and Lipofectamine 2000 
(LF), two standard reagents for in vitro delivery of nucleic acids 
(Figure  7 a). [ 23 ] KIF11 siRNA transfected with RNAiMAX and LF 
decreased the cell viability to 57% ± 2% and 32% ± 4%, respec-
tively, when normalized to nontreated cells. Viability of the cells 
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 Figure 5.  Stabilization of siRNA by THS–PAMAM and PAMAM against 
enzymatic degradation by RNase A. a) Digestion experiment of siRNA, 
PAMAM-siRNA and THS–PAMAM–siRNA monitored by agarose gel elec-
trophoresis. b) Quantifi cation of fl uorescence, which corresponds to the 
concentration of intact siRNA, in the digestion experiments: siRNA (), 
PAMAM–siRNA () and THS–PAMAM siRNA ().
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stayed at 96% ± 14% when RNAiMAX and scrambled siRNA 
was used, indicating that this transfection agent was not toxic. 
However, LF with scrambled siRNA reduced cell viability signif-
icantly ( p = 0.0063) to 48% ± 13%. Similar results were obtained 
with LF in the absence of RNA (Figure S8, Supporting Informa-
tion). Thus, the pronounced reduction in cell viability observed 
for siRNA-loaded LF was mainly due to the toxicity of the trans-
fection agent, and only partially caused by KIF11 silencing. 
Taking this into account, the transfection effi ciency of THS–
PAMAM for KIF11 siRNA was slightly lower than the effi ciency 
of LF and about two thirds of the effi ciency of RNAiMAX. How-
ever, LF exhibited unspecifi c toxicity against the investigated 
cell line, while THS–PAMAM was not cytotoxic. 
 To further evaluate the effectiveness of siRNA delivery by 
THS–PAMAM, the knockdown of another gene was investigated. 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) is a 
marker protein commonly used in such studies. [ 24 ] Therefore, 
siRNA against GAPDH was transfected with THS–PAMAM 
into U87 cells (Figure  7 b). The protein–polymer conjugate 
effi ciently silenced GAPDH expression at 10 pmol per well 
siRNA. In comparison, PAMAM had only minor effects on 
the GAPDH level, even when 10 pmol per well of siRNA was 
transfected with the dendrimer. Therefore, PAMAM alone has 
only very weak transfection effi cacy, but encapsulated in THS, 
it becomes a potent siRNA transfection agent. RNAiMAX was 
even more effi cient and showed silencing already at 0.1 pmol 
per well siRNA. However, the gold standard for in vitro siRNA 
delivery has its drawbacks, for example it cannot be further 
functionalized on its surface and it is not suitable for in vivo 
experiments. [ 1b ] 
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 Figure 6.  Cell uptake of THS. a) Flow cytometry of different cell lines incubated with THS–Atto647: MCF-7 (red), PC-3 (brown), HUVEC (light green), 
CHO-K1 (dark green), U87 (orange) and as a control U87 in the absence of THS–Atto647 (blue). b) Confocal microscopy images of U87 cells incubated 
with THS–Atto647 for 30 min and 2 h: THS–Atto647 (green), nucleus (blue), left: cell membrane (red), right: acidic compartments (red); scale bars: 
20 µm.
 Figure 7.  siRNA delivery into U87 cells. a) Normalized viability of U87 cells transfected with KIF11 siRNA (blue) or scrambled siRNA (red) with either 
THS–PAMAM, PAMAM, Lipofectamine RNAiMAX or Lipofectamine 2000 (10 pmol siRNA per well in all cases). (Two sided t-test; THS–PAMAM 
 n = 12 each; PAMAM, Lipofectamine RNAiMAX, and Lipofectamine  n = 4 each; *:  p < 0.05; **:  p < 0.01; ****:  p < 0.0001). b) Representative western 
blots of GAPDH expression in U87 cells transfected with GAPDH siRNA with either THS–PAMAM, PAMAM, or Lipofectamine RNAiMAX.
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 2.5.  Decoration of THS–PAMAM with a Cell-Penetrating Peptide 
 In contrast to the two commercial transfection reagents, THS–
PAMAM can be further modifi ed on its surface. To show this 
versatility of the protein cage and to perform siRNA-induced 
gene silencing in another cell type, THS–PAMAM was deco-
rated with the cell-penetrating peptide TAT, which is derived 
from the transactivator of transcription (TAT) of human immu-
nodefi ciency virus (HIV). [ 25 ] The peptide is known to facilitate 
the internalization of drugs, proteins, and nanoparticles. [ 18 ] 
TAT was conjugated to the lysines of THS–PAMAM with a bis-
arylhydrazone linker (Figure S9, Supporting Information). An 
increase in molar mass of the THS subunits due to the con-
jugation of TAT was observed in SDS–PAGE (Figure S10a, 
Supporting Information). On average, 6.7 ± 0.2 TAT peptides 
were conjugated to each THS–PAMAM, as determined from 
the UV absorbance band at 354 nm (Figure S10b, Supporting 
Information). 
 TAT is known to facilitate uptake of cargo into PC-3 cells. [ 26 ] 
Therefore, these cells were incubated with a fl uorescently 
labeled, TAT-decorated THS, and analyzed by fl ow cytom-
etry ( Figure  8 a). The median fl uorescence of the cells with 
TAT–THS–Atto647 increased about 630 times compared with 
the background fl uorescence of PC-3 cells. In comparison, 
unmodifi ed THS–Atto647 showed only minor uptake by PC-3 
cells, which manifested itself in an increased fl uorescence of 
a factor of three. The interaction of TAT–THS–Atto647 with 
PC-3 cells was investigated by confocal microscopy (Figure  8 b). 
After 30 min of incubation, TAT–THS–Atto647 was located at 
the cell membrane of PC-3 cells and had not yet entered the 
cells. After 2 h of incubation, TAT–THS–Atto647 was inter-
nalized into cells. The protein cage was not co-localized with 
LysoTracker, i.e., with acidic compartments. As expected, it 
was also not located at the cell nucleus. Concluding, the cell-
penetrating peptide is able to traffi c the protein cage into these 
cells. After a phase where TAT–THS–Atto647 is located at the 
cell membrane, the protein cage is translocated to the cytosol. 
These fi ndings suggest that the uptake of TAT–THS–Atto647 by 
PC-3 and of THS–Atto647 by U87 cells follow different path-
ways. Taking into account that the general uptake mechanisms 
of TAT and its diverse cargo are still under scientifi c debate, [ 27 ] 
it cannot be concluded whether TAT–THS enters the cells 
through the endosomal pathway and escapes the endosome, or 
if it reaches the cytosol by macropinocytosis. [ 28 ] Nevertheless, 
these results confi rm that TAT can translocate relative large 
proteins into cells that would otherwise not internalize these 
proteins. [ 29 ] 
 TAT-modifi ed THS–PAMAM was used to deliver siRNA into 
PC-3 cells. To this end, TAT–THS–PAMAM was loaded with 
10 pmol per well KIF11 siRNA and scrambled siRNA, respec-
tively, and added to PC-3 cells. As control, the same experi-
ments were performed with THS–PAMAM that lacked the cell 
penetrating peptide. The viability of cells incubated with KIF11 
siRNA-loaded TAT–THS–PAMAM dropped to 69% ± 6% com-
pared with nontreated cells and to 79% ± 8% ( p = 0.014) when 
compared with the cells that were treated with TAT–THS–
PAMAM carrying scrambled siRNA ( Figure  9 ). In contrast, the 
cell viability of THS–PAMAM without cell penetrating peptide 
enclosing KIF11 siRNA (88% ± 5%) or scrambled siRNA (90% 
± 4%) varied only minimally. These results show that TAT-mod-
ifi ed THS–PAMAM is able to transfect siRNA into PC-3 cells 
and that the presence of the cell-penetrating peptide is crucial 
for this purpose. The performance of TAT–THS–PAMAM in 
delivering KIF11 siRNA into PC-3 cells is roughly the same as 
THS–PAMAM delivering siRNA into U87 cells. 
 3.  Conclusion 
 siRNA is a promising drug as it can be used to silence the 
expression of disease-related proteins. Moreover, it is a pow-
erful tool for in vitro molecular biology studies. However, 
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 Figure 8.  Uptake of TAT-THS by PC3 cells. a) Flow cytometry of PC-3 (orange), PC-3 incubated with TAT–THS–Atto647 (red) and PC-3 incubated with 
THS-Atto647 (blue). b) confocal microscopy images of PC-3 cells incubated with TAT-THS–Atto647 for 30 min and 2 h; TAT–THS–Atto647 (green), 
nucleus (blue), left: cell membrane (red), right: acidic compartments (red); scale bars: 20 µm.
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transfection reagents have to be used to traffi c the oligonucleo-
tide into cells. We present a delivery platform for siRNA based 
on the protein cage THS. PAMAM was covalently bound into 
the THS in order to equip the protein with the ability to bind 
and release nucleic acids. THS–PAMAM stabilized siRNA 
against degradation by RNase. THS was taken up by U87 cells 
but not by PC-3, HeLa, MCF-7, CHO-K1 or HUVEC cells. Sig-
nifi cant siRNA-induced inhibition of proliferation and silencing 
of GAPDH in U87 was achieved with THS–PAMAM, whereas 
PAMAM alone was highly toxic to the cells and not effi cient in 
delivering siRNA. Additional modifi cation of THS with the cell-
penetrating peptide TAT allowed for uptake and siRNA delivery 
into cells that otherwise do not internalize the protein cage. 
 THS–PAMAM conjugates offer several advantages over free 
PAMAM as a transfection agent. PAMAM is shielded within 
the protein cage. The dendrimer can otherwise directly interact 
with cells, which causes cytotoxicity and initiates uncontrolled 
uptake. [ 30 ] Decoration of THS with TAT is an example for the 
versatility of the THS delivery platform. It shows that the pro-
tein cage can be easily modifi ed with functional ligands, which 
will allow engineering it further into a targeted drug delivery 
system. 
 The properties of the protein–polymer conjugate to bind, 
protect and release guests make it an interesting delivery plat-
form with applications well beyond the delivery of siRNA. For 
example, PAMAM inside the THS could be used to bind a high 
number of small drugs or MRI-contrast agents. Moreover, the 
THS could be used to deliver other therapeutic macromol-
ecules or oligomers, such as pharmaceutically active peptides 
and small proteins. In conclusion, THS–PAMAM represents 
a promising and versatile delivery platform for siRNA and has 
considerable potential as nontoxic nanodelivery system for ther-
apeutic payloads. 
 4.  Experimental Section 
 Materials : The THS mutant was expressed and purifi ed as 
previously reported by Bruns et al. [ 11a,b ] All chemicals were purchased 
from Sigma-Aldrich, unless stated otherwise. Maleimido trioxa-6-
formylbenzamide (MTFB), succinimidyl-6-hydrazinonicotinamide 
acetone hydrazone (HyNic), tetra ethylene glycol pentafl uorophenyl ester 
4-formylbenzamide (PEG 4 -PFB), and 6-hydrazinonicotinamide acetone 
hydrazone-GRKKRRQRRRPPQ-NH 2 (TAT–HyNic) were purchased from 
Solulink (USA). Following cell lines were purchased from ATCC (USA): 
breast adenocarcinoma cells MCF-7 (ATCC HTB-22), Chinese hamster 
ovary cells CHO-K1 (ATCC CCL-61), vascular endothelium cells HUVEC 
(ATCC CRL-1730), glyoblastoma cells U-87 MG (ATCC HTB-14) and 
cervical cancer cells HeLa (ATCC CCL-2). Prostate cancer cells PC-3 
(ATCC CRL-1435) were a kind gift of Prof. T. Mindt’s group (University 
Hospital Basel) and purchased from HPA Culture Collections (UK). 
Centrifugal fi lters were purchased from Merck Millipore (USA), RNase 
A from Roche (Switzerland), Atto dyes from ATTO-TEC (Germany), 
GelRed from Biotium (USA), cell culture fl asks and 24- and 96-well 
plates from BD Bioscience (USA) and 8-well microscope chamber slides 
from Nunc (USA). 6X MassRuler DNA Loading Dye, Hoechst 33342, 
CellMask orange, LysoTracker Red DND-99, penicillin–streptomycin mix, 
100× nonessential amino acids solution, silencer KIF11 (Eg5) siRNA 
(sequence not revealed by the supplier), Lipofectamine 2000 (LF), 
and Lipofectamine RNAiMAX, were purchased from Life Technologies 
(USA). Scrambled siRNA with the sequence 5′-AGG UAG UGU AAU 
CGC CUU GTT-3′ was obtained from Microsynth (Switzerland). DMEM, 
opti-MEM, the Micro BCA protein assay kit, the super signal west pico 
chemiluminescent substrate and Silencer select positive control GAPDH 
siRNA as well as nuclease free PBS buffer (10×) and nuclease-free water 
were purchased from Thermo Scientifi c (USA). 1.4 nm Monomaleimido 
nanogold (AuNP-mal) and 1.4 nm mono-sulfo-NHS nanogold (AuNP–
NHS) were obtained from Nanoprobes, USA. 
 Methods : All concentrations are given as end concentrations in 
the reaction mixture. Concentration measurements were performed 
with NanoDrop 2000c (Thermo Scientifi c, USA), if not stated 
otherwise, and calculated with following extinction coeffi cients: THS 
ε 280nm = 210 880 M −1 cm −1 , [ 11a ] hydrazone bond ε 354nm = 29 000 M −1 cm −1 
(according to the manufacturers protocol; Solulink, USA), [ 19a ] siRNA ε 260nm = 
300 000 M −1 cm −1 (determined by absorption measurements at different 
concentrations). Structures of proteins were rendered with the software 
USCF Chimera V1.10.1. [ 31 ] As there is no structural data set of the open 
conformation of THS available in the databases, the cryo-EM density map 
of the structural similar thermosome Mm-cpn in its open conformation is 
shown. [ 32 ] The location of cysteine on the inner surface of the beta subunits 
was determined by sequence alignment between the THS mutant and 
Mm-cpn using ClustalW2 ( http://www.ebi.ac.uk/Tools/msa/clustalw2/ ). A 
model of PAMAM (modifi ed with the bisaryl hydrazone linker that results 
from the reaction of HyNic and MTFB) was computed using the software 
ChemBio3D Ultra 14 by running a MM2 molecular dynamics simulation to 
relax the molecule, followed by MM2 energy minimization. The resulting 3D 
model was placed into Mm-cpn using Chimera. 
 SDS-PAGE : SDS-PAGE gels were prepared according to Laemmli’s 
protocol. [ 33 ] Subsequently to denaturing the samples at 95 °C for 3 min 
the samples were loaded on 12% SDS–PAGE gel and run for 70 min at 
constant voltage of 200 V. A fl uorescence image (Bio-Rad Gel doc EZ 
imager) was recorded before Coomassie blue staining. 
 Native-PAGE : The samples were mixed with 5× loading buffer 
(150 × 10 −3  M Tris/HCl pH 6.8, 70% glycerol, 0.01% w/v bromophenol 
blue), loaded on a 4%–20% precast gradient gel (10 well, mini-protean, 
Bio-Rad, USA) and run in Tris-glycine buffer (25 × 10 −3  M Tris pH 8.25, 
192 × 10 −3  M glycine) for 3.5 h at constant 100 V. 
 Transmission Electron Microscopy : For Figure S4 (Supporting 
Information) 5 µL of 20 × 10 −9  M THS–PAMAM solution was deposited 
for 60 s on a glow-discharged grid. For Figure S6 (Supporting 
Information), 0.1 × 10 −6  M THS–PAMAM and 0.1 × 10 −6  M siRNA was 
incubated for 10 min at RT and afterward 100× diluted with PBS pH 7.4 
(1 × 10 −9  M THS–PAMAM and 1 × 10 −9  M siRNA). The dilution step was 
necessary to identify aggregates; else the THS–PAMAM would be too 
densely packed to do so. The solutions were then deposited for 60 s on 
a glow-discharged grid, washed twice with ddH 2 O and negatively stained 
twice with 1% uranyl acetate solution. The sample was imaged with a Fei 
Morgagni 268 D TEM at an accelerating voltage of 80 kV. 
 Cryo-Transmission Electron Microscopy : A 4 µL aliquot of sample was 
adsorbed onto glow-discharged holey carbon-coated grid (Quantifoil, 
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 Figure 9.  siRNA delivery into PC-3 cells. Normalized viability of PC-3 
cells transfected with KIF11 siRNA (blue) or scrambled siRNA (red) with 
either TAT–THS–PAMAM or THS–PAMAM (10 pmol siRNA per well in all 
cases). (Two sided t-test; TAT–THS–PAMAM  n = 4 each; THS–PAMAM 
 n = 4 each; *:  p < 0.05).
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Germany), blotted with Whatman fi lter paper and vitrifi ed into liquid 
ethane at −178 °C using a vitrobot (FEI company, Netherlands). Frozen 
grids were transferred onto a Philips CM200-FEG electron microscope 
using a Gatan 626 cryo-holder (GATAN, USA). Electron micrographs 
were recorded at an accelerating voltage of 200 kV and a nominal 
magnifi cation of 50000×, using a low-dose system (10 e − per Å 2 ) and 
keeping the sample at −175 °C. Defocus values were −4 µm. Micrographs 
were recorded at 4K × 4K CMOS camera (TVIPS, Germany). 
 Electrophoretic Mobility Shift Assays : [ 34 ] Samples were run for 40 min 
at constant voltage of 100 V on a 1.2% agarose gel in TRIS-acetate-EDTA 
(TAE) buffer. The gel was stained with GelRed stain and a UV-image was 
recorded (Bio-Rad Gel doc EZ imager). THS–PAMAM concentration of 
6 × 10 −6  M and siRNA concentration of 2 × 10 −6  M were used for the 
samples. The samples were incubated for 10 min at RT. To selected 
samples a fi nal concentration of 0.4% SDS was added and incubated for 
another 10 min at RT. 10 µL of each sample was mixed with 2 µL loading 
buffer (6× MassRuler DNA Loading Dye) and loaded on the gel. 
 Digestion Assays : siRNA (2.8 µg, 2 × 10 −6  M ) was incubated with 
either PAMAM (8.53 µg, 6 × 10 −6  M ), 6 × 10 −6  M THS–PAMAM or on 
its own for 10 min at 37 °C in 100 × 10 −3  M phosphate buffer pH 7.5 
with 150 × 10 −3  M NaCl. Then, 50 U mL −1 RNase A was added and the 
solutions were incubated at 37 °C for defi ned time intervals (0 min, 
5 min, 10 min, 20 min, 30 min, 40 min, and 60 min). SDS was added 
to a fi nal concentration of 0.4% to specifi ed samples. Immediately 
thereafter, the samples were analyzed by agarose gel electrophoresis and 
imaged with a fl uorescence gel reader. Fluorescence intensity analysis 
was performed with the software ImageJ 1.48v (NIH, USA), whereas the 
fl uorescence was normalized to the fl uorescence of the samples that 
were incubated for 0 min. 
 THS–PAMAM Conjugation : THS (1.14 mg, 10 × 10 −6  M ) was reacted 
with MTFB (121 µg, 2 × 10 −3  M ; 200 equiv. to THS; 12.5 equiv. to subunits) 
in buffer A (100 × 10 −3  M sodium phosphate pH 7.5, 150 × 10 −3  M NaCl) 
for 2.5 h at RT under shaking. Subsequently, the buffer was exchanged to 
buffer B (100 × 10 −3  M sodium phosphate pH 6.5, 150 × 10 −3  M NaCl). 
PAMAM (0.85 mg, 500 × 10 −6  M ) was modifi ed in buffer B at RT for 
2 h under shaking with a tenfold excess of HyNic (174 µg, 5 × 10 −3  M ). 
After purifi cation with centrifugal fi lters, modifi ed THS and modifi ed 
PAMAM were mixed to a fi nal concentration of 10 × 10 −6  M (0.95 mg) 
and 500 × 10 −6  M (0.71 mg), respectively. The solution was incubated 
overnight in buffer B at RT under shaking. A kinetic study of the 
conjugation reaction showed that 80% of the THS–PAMAM bonds 
formed within 3 h (Figure S2, Supporting Information). Separation of 
THS–PAMAM from excess of PAMAM was carried out by size exclusion 
chromatography (HiPrep 16/60 Sephacryl S-200 column) in SEC buffer 
(20 × 10 −3  M Tris/HCl pH 7.5, 100 × 10 −3  M NaCl, 1 × 10 −3  M EDTA, 
0.02% NaN 3 ). Chromatograms at 280 and 350 nm were recorded and 
the peaks were pooled and concentrated. NaN 3 was removed and buffer 
was exchanged to the buffers needed for the various further experiments 
by centrifugal fi ltration. All conjugation products were purifi ed with 
Amicon centrifugal fi lters (THS: MWCO: 100 kDa; PAMAM: MWCO: 
3 kDa) by at least fi ve concentration–dilution cycles. Buffer exchange and 
concentration steps were carried out by centrifugal fi ltration in the same 
way. 
 Molecular Substitution Ratio (MSR) of THS–MTFB : To determine 
the degree of modifi cation of THS with MTFB, THS–MTFB was 
reacted with 2-hydrzinopyridine. 1.7 × 10 −6  M THS–MTFB was reacted 
with 450 × 10 −6  M 2-hydrazinopyridine in 100 × 10 −3  M sodium citrate 
buffer pH 5.0 for 30 min at 37 °C. The absorbance was measured at 
350 nm, whereas the absorbance of the negative control (450 × 10 −6  M 
2-hydrazinopyridine) was subtracted. 
 MSR of PAMAM–HyNic : PAMAM was modifi ed with HyNic as 
described above, but the excess of HyNic over PAMAM was varied 
between 6 and 100. To measure the MSR, 10 × 10 −6  M PAMAM–
HyNic was incubated with 450 × 10 −6  M 4-nitrobenzaldehyde in buffer 
A for 30 min at 37 °C. The absorbance was measured at 390 nm 
(ε 390 nm = 24 000 M −1 cm −1 ) [ 11a ] using a SpectraMax M5 e (Molecular 
Device) spectrometer, and the absorbance of the negative control 
(450 × 10 −6  M 4-nitrobenzaldehyde) was subtracted. The degree of 
modifi cation could be controlled by the concentration of HyNic in the 
reaction mixture (Figure S1, Supporting Information). 
 Characterization of THS–PAMAM Conjugates : For SDS-PAGE 
analysis of the conjugate, PAMAM–HyNic was labeled with Atto647-
 N -Hydroxysuccinimide ( NHS) by reacting PAMAM–HyNic 
(0.19 µg, 133 × 10 −6  M ) with a fi vefold excess of Atto647–NHS (54.0 µg, 
666 × 10 −6  M ) in buffer A for 1.5 h at RT in the dark. Unbound Atto647 was 
separated by dialysis (MWCO: 10 kDa) against 0.1  M NaCl (exchanged 
after 2 h, 4 h, and 8 h). Then, the sample was concentrated and the 
buffer exchanged as described above. Some of Atto647–PAMAM–HyNic 
was further linked to THS-FB. 
 Preparation of THS–Atto647 : Cysteines of THS were labelled with 
Atto647-maleimide (Atto647-mal) by reacting THS with a 40-fold 
excess of Atto647-mal. To this end, 7 × 10 −6  M THS was reacted with 
280 × 10 −6  M Atto647-mal in buffer B (100 × 10 −3  M sodium phosphate 
pH 6.5, 150 × 10 −3  M NaCl) for 2.5 h at RT under shaking. THS–Atto647 
was purifi ed from free dye with HiTrap desalting columns (Sephadex 
G25 Superfi ne; GE Healthcare, UK). Concentration and buffer exchange 
was performed with centrifugal fi lters (MWCO: 100 kDa). 
 Preparation of THS–AuNP : 2.3 × 10 −6  M THS was reacted with a 20-fold 
excess of 1.4 nm monomaleimido nanogold (AuNP-mal) (46 × 10 −6  M ) in 
buffer B for 2 h at RT under gentle shaking. The sample was purifi ed by 
size exclusion from unreacted AuNP by SEC as described in the method 
part of the paper (THS–PAMAM conjugation). 
 Preparation of THS–PAMAM–AuNP : 10 × 10 −6  M PAMAM was modifi ed 
with 30 × 10 −6  M 1.4 nm mono-sulfo-NHS-nanogold (AuNP–NHS) and 
100 × 10 −6  M HyNic in buffer A for 1.5 h at RT under gentle shaking. Free 
HyNic was removed with centrifugal fi lters (MWCO: 3 kDa). THS–MTFB 
was modifi ed with AuNP–PAMAM–HyNic as described in the paper for 
the modifi cation of THS–MTFB with PAMAM–HyNic. 
 siRNA Binding to THS–PAMAM : THS–PAMAM (3 × 10 −6 M) 
was incubated with a fi vefold excess of scrambled siRNA (21.0 µg, 
15 × 10 −6  M ) in RNase-free buffer A for 10 min at 37 °C. Unbound siRNA 
was removed by extensive centrifugal fi ltration (MWCO: 100 kDa). 
siRNA on the THS–PAMAM was quantifi ed by UV/Vis spectroscopy. To 
this end, the absorbance spectrum of THS–PAMAM in the absence of 
siRNA was normalized to the absorbance of THS–PAMAM–siRNA at 
354 nm. The concentration of siRNA was calculated from the difference 
in absorbance at 260 nm. 
 Preparation of TAT–THS–PAMAM : THS–PAMAM (5.4 × 10 −6  M ) was 
modifi ed with a 20-fold excess of tetra ethylene glycol pentafl uorophenyl 
ester 4-formylbenzamide (PEG 4 -PFB) ( 4 , 6.1 µg, 108 × 10 −6  M ) in buffer A 
for 2 h at RT under shaking. The product was purifi ed and the buffer was 
exchanged to buffer B. The resulting PFB–THS–PAMAM (5.4 × 10 −6  M ) 
was reacted with a 20-fold excess of TAT–HyNic ( 5 , 20.0 µg, 108 × 10 −6  M ) 
in buffer B overnight at RT under shaking. Free TAT–HyNic was separated 
from TAT–THS–PAMAM by fi lter centrifugation (MWCO: 100 kDa). 
 Cell Cultures : All cell lines were grown at 37 °C under a 5% CO 2 
atmosphere in the following cell culture media (further labeled as 
“normal cell growth conditions”): HeLa & PC-3: Dulbecco’s modifi ed 
Eagle medium (DMEM); CHO-K1: Roswell Park Memorial Institute 
medium 1640 (RPMI); HUVEC: DMEM, 20 U mL −1 Heparin, 30 µL mL −1 
endothelial cell growth supplement (ECGS); MCF-7 and U-87 MG: 
minimum essential medium Eagle (MEME) with nonessential amino 
acids (NEAA). All media were with 10% fetal calf serum (FCS), 
200 U mL −1 penicillin and 200 µg mL −1 streptomycin. When cells 
reached a confl uency of about 80%, they were split and subcultured by 
trypsinization. 
 Live Cell Images : For live images 50 000 cells were seeded in eight-well 
microscope chamber slides for 24 h in normal cell culture conditions. 
Before adding the samples to the cells, old medium was removed; new 
medium was added to such an amount that in the end the total volume 
with sample resulted to be 100 µL. After 10 min or 2 h incubation under 
normal cell growing conditions the cells were washed with phosphate 
buffered saline (PBS) and 400 µL serum-free medium was added. To 
stain nuclei, cell membrane and/or acidic compartments, the cells were 
incubated in 0.2 µg mL −1 Hoechst 33342 for 25 min and 2.5 µg mL −1 
CellMask orange for 5 min or 20 × 10 −9  M LysoTracker Red for 10 min, 
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respectively. Subsequently, cells were washed with PBS and wells were 
refi lled with 400 µL PBS. Cell imaging was performed by confocal 
laser scanning microscopy (CLSM) with a Zeiss 510-META/Confocor2 
microscope equipped with a laser diode (405 nm), argon laser (488 nm), 
and a helium/neon laser (633 nm); and a 40× water-immersion objective 
(Zeiss C-Apochromat 40×/1.2 W corr). The samples were excited at 
405 nm, 514 nm (NFT mirror 545), or 633 nm (NFT mirror 545) and the 
emission was collected with a broad pass fi lter at 420–480 nm, a broad pass 
fi lter 560–615 nm or an long pass fi lter at 650 nm, respectively. The pinholes 
were set to 61, 80, and 92 µm, respectively. The cells were imaged in 
multitrack mode with a resolution of 1024 × 1024 pixels (225 µm × 225 µm) 
with a pixel time of 25.6 µs. The images were cropped to 512 × 512 pixels 
(112 µm × 112 µm) using LSM Image Browser (Zeiss). 
 FACS : For FACS measurements, 100 000 cells were seeded into 
24-well plates, fi lled up with 1.5 mL cell culturing medium and incubated 
under normal cell culture conditions. After 2 d, the medium was 
aspirated, THS–Atto647 or TAT–THS–Atto647 were added and fi lled up 
to 100 µL with cell culturing medium so that the fi nal dye concentration 
was 150 × 10 −9  M . After 2 h of incubating under normal cell grow 
conditions, the cells were washed with PBS, trypsinized, and put on ice. 
FACS measurements were performed with a FACSCanto II (BD, USA) with 
at least 10 000 cells. The cells were excited with a HeNe laser at 633 nm 
and the emitted light passed through a Band Pass 660/20 fi lter before 
reaching the detector. Data were processed with FlowJo Vx (Tree Star, 
USA) and a histogram of fl uorescence of single cells only was plotted. 
 Dynamic Light Scattering : DLS measurements of 0.1 × 10 −6  M THS–
PAMAM, and 0.1 × 10 −6  M THS–PAMAM incubated for 10 min at RT with 
0.1 × 10 −6  M siRNA in PBS pH 7.4 were performed on a Zetasizer ZSP 
(Malvern, USA) instrument. The backscattering at 173° was recorded at 
25 °C with an equilibrium time of 30 s. The data were analyzed with the 
instrument’s software. Each experiment was carried out four times. The 
reported data represents the average of these four measurements, based 
on particle number distributions. All samples were measured six times. 
 KIF11 siRNA Delivery : Silencer KIF11 (Eg5) siRNA was used as active 
siRNA and scrambled siRNA was used as negative control. KIF11 siRNA 
or scrambled RNA was bound to THS–PAMAM or TAT–THS–PAMAM 
as described above. siRNA transfection was performed according to 
the reversed siRNA transfection protocol from the manufacturer of 
LF (Life Technologies, USA). For this purpose THS–PAMAM–siRNA, 
TAT-THS–PAMAM–siRNA, PAMAM–siRNA (in a ratio of 3.8 eq. PAMAM 
to 1 eq. siRNA, which corresponds to the ratio in THS–PAMAM–
siRNA), 0.3 µL Lipofectamine RNAiMAX and siRNA, or 0.5 µL LF 
and siRNA were pipetted into wells of a 96-well plate and fi lled up to 
10 µL with RNase free buffer A (100 × 10 −3  M sodium phosphate pH 
7.5, 150 × 10 −3  M NaCl) so that a siRNA concentration of 1 × 10 −6  M 
was achieved. After 10 min, 5000 cells were added to each well and fi lled 
up to 100 µL with medium without serum and antibiotics, resulting in a 
fi nal siRNA concentration of 100 × 10 −9  M . This corresponds to 10 pmol 
of siRNA per well. All experiments were conducted with KIF11 siRNA and 
scrambled siRNA to calculate the viability decrease due to KIF11 siRNA. 
The medium was exchanged to normal growth medium after 5 h. The 
cells were incubated 72 h in total under normal growth conditions. The 
cell viability was determined with the cell counting kit-8 (CCK-8; Sigma-
Aldrich). Absorbance of converted CCK-8 was measured at 450 nm with 
a SpectraMax M5 e plate reader (Molecular Devices). As background 
CCK-8 in medium was measured, which was subtracted from the data. 
The viabilities of cells treated with siRNA and scrambled RNA were 
normalized to the viability of untreated cells. All measurements were 
performed in multiple, whereas  n indicates the number of experiments. 
All data were fi rst tested with Prism (GraphPad, USA) to confi rm that 
they are normally distributed and have the same variance. As this was 
the case, two-sided Student’s t-test was applied, whereas signifi cance 
level was set to  p < 0.05 (*),  p < 0.01 (**) and  p < 0.0001 (****). Data 
are presented as mean ± SD. 
 GAPDH siRNA Delivery : The procedure of a previously published 
protocol was followed with several modifi cations. [ 24 ] 24 h before the 
experiment, 5000 U87 cells were plated in 100 µL per well in a 96-well 
plate and incubated at 5% CO 2 and 37 °C. For every sample, four wells 
were plated. After 24 h, samples were prepared by adding 0.4–40 pmol 
of GAPDH siRNA (volume 20 µL) in opti-MEM, and mixing it with either 
blank opti-MEM, opti-MEM containing Lipofectamine RMAiMAX (0.3 µL 
per pmol of siRNA), THS–PAMAM (in a ratio of 4:1 siRNA to THS–
PAMAM) or PAMAM (in a ratio of 4:1 siRNA to PAMAM) in 20 µL (total 
volume 40 µL). The samples were incubated at room temperature for 
30 min. 10 µL of sample were added to each well (fi nal concentrations of 
0.1–10 pmol siRNA per well). After 72 h, the media was removed from 
cells and they were washed three times with PBS. 60 µL of lysis buffer 
was added to the fi rst well, which was incubated for 5 min and then 
transferred to the second, third, and fourth well of each sample with 
5 min incubation in each (fi nal volume of 60 µL containing a mixture of 
the cell lysate of all four wells, thus physically averaging the results of four 
experiments). The protein concentration of the cell lysate was quantifi ed 
with the micro-BCA protein assay kit. 15 µg total protein of each sample 
was then mixed in 5× SDS protein loading buffer and heated at 95 °C for 
10 min. After heating, the samples were loaded into a 10% TGX stain 
free acrylamide gel and electrophoresed at 120 V for 50 min. The gel was 
removed from the cassette and imaged on an EZdoc one touch imager 
(BioRAD) using the TGX stain free method activating for 5 min. This 
image was analyzed in ImageJ to verify consistent loading of each well by 
quantifying the band at 40 kDa (see Figure S11, Supporting Information 
for the loading control gels that correspond to the Western blots of the 
manuscript). The gels were then transferred to nitrocellulose membranes 
via a biometra FASTblot semidry transfer system at a constant 80 mA for 
25 min. The membranes were blocked in 5% milk in TBS buffer overnight 
at 40 °C. The next morning the blocking solution was removed. 15 mL 
of 5% milk in TBS containing 1:10 000 mixture of primary monoclonal 
mouse antiGAPDH antibody was added to each membrane. They were 
incubated at room temperature for 2 h. The membranes were then 
washed three times in TBST buffer for 10 min. The second incubation 
was done in 15 mL 5% milk in TBS containing 1:10 000 goat antimouse 
HRP conjugated antibody for 1 h. The membranes were washed three 
more times at 10 min each in TBST buffer and then dried. Supersignal 
west pico chemiluminescent substrate was added as per manufacturer’s 
directions and imaged on a Bucher biotec fl uorescence imaging system 
equipped with s FujiFilm Las-4000 camera. Images were recorded with 
the Las-4000 software and analyzed in ImageJ to determine the GAPDH-
protein level of each sample. 
 Supporting Information 
 Supporting Information is available from the Wiley Online Library or 
from the author. 
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